{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:57:19Z","timestamp":1773421039219,"version":"3.50.1"},"posted":{"date-parts":[[2026,3,13]]},"group-title":"In Review","reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,11]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <italic>\n                    <bold>Background:<\/bold>\n                  <\/italic>\n                  Although temozolomide (TMZ) is widely used for glioma treatment, its therapeutic benefit is limited by acquired resistance and recurrence, facilitated by intratumor heterogeneity. Mutational signatures can inform tumor evolution and reveal alterations associated with treatment response.\n                  <italic>\n                    <bold>Methods:<\/bold>\n                  <\/italic>\n                  We performed a molecular analysis of 96 glioma recurrences with sufficient private single-base substitution (SBS) relative to their matched primary tumors, stratified by their dominant SBS.\n                  <italic>\n                    <bold>Results:<\/bold>\n                  <\/italic>\n                  Four groups were identified: SBS11 (TMZ, n=38), SBS1\/5 (aging, n=32), SBS6\/15\/21\/26 (microsatellite instability (MSI), n=13), and other dominant SBSs (n=13). Recurrences with dominant SBS11 showed markedly higher acquired mutational counts than the other groups (1338 vs 59 (aging) vs 57 (MSI) vs 57 (other); p&lt;0.01). Mutations in\n                  <italic>SYNE2<\/italic>\n                  ,\n                  <italic>SZT2<\/italic>\n                  , and\n                  <italic>FBN3<\/italic>\n                  were exclusive to recurrences with dominant or second-dominant SBS11 (n=41), and 85% (35\/41) harbored a mutation in at least one of these genes. Among TMZ-associated recurrences, SBS23 was frequent (44%, 18\/41) and was associated with higher acquired mutational counts (2089 vs 1188; p=0.018) and more IDH-wildtype tumors (67% vs 30%; p=0.037) compared with cases lacking SBS23 dominance.\n                  <italic>MAPKBP1<\/italic>\n                  mutations were enriched in SBS23-positive recurrences (56% (10\/18) vs 0% (0\/23); p&lt;0.001). Aging-dominant recurrences showed more frequent acquired chromosome 16q losses (22% vs 8% (TMZ) vs 0% (MSI) vs 0% (other); p&lt;0.05), which were associated with an increased fraction of the genome altered when compared with diploid chromosome 16q (15% vs 7%; p=0.01).\n                  <italic>\n                    <bold>Conclusions:<\/bold>\n                  <\/italic>\n                  Collectively, these findings show that signature-based grouping of recurrences can refine molecular characterization after therapy and nominate candidate biomarkers linked to resistance.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9093330\/v1","type":"posted-content","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:14:22Z","timestamp":1773414862000},"source":"Crossref","is-referenced-by-count":0,"title":["Mutational signature stratification of recurrent gliomas reveals distinct patterns of genomic traits"],"prefix":"10.21203","author":[{"given":"Joana","family":"Peixoto","sequence":"first","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Miguel","family":"Castanho","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"B\u00e1rbara","family":"Soares-Ferreira","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Beatriz","family":"Esteves","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Patr\u00edcia","family":"Ferreira-Torre","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Nuno","family":"Higino","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Gabriela","family":"Silva","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Lorenzo","family":"Ferrando","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Specialties, University of Genoa, Italy"}]},{"given":"Yingjie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}]},{"given":"Lu\u00eds","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Bruno","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal"}]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Arnaud Da Cruz","family":"Paula","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]},{"given":"Jorge","family":"Lima","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, Porto, Portugal"}]}],"member":"297","reference":[{"issue":"9","key":"ref1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ncpneuro0289","article-title":"Epidemiology and molecular pathology of glioma","volume":"2","author":"Schwartzbaum JA","year":"2006","unstructured":"Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2(9):494\u2013503 quiz 516. https:\/\/doi.org\/10.1038\/ncpneuro0289","journal-title":"Nat Clin Pract Neurol"},{"issue":"12 Suppl 2","key":"ref2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa269","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom QT","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS, CBTRUS Collaborators (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol 22(12 Suppl 2):iv1\u2013iv96. https:\/\/doi.org\/10.1093\/neuonc\/noaa269","journal-title":"Neuro Oncol"},{"issue":"12","key":"ref3","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.3390\/ijms25126733","article-title":"Recurrent glioblastoma \u2014 molecular underpinnings and evolving treatment paradigms","volume":"25","author":"Chang C","year":"2024","unstructured":"Chang C, Chavarro VS, Gerstl JVE, Blitz SE, Spanehl L, Dubinski D, Valdes PA, Tran LN, Gupta S, Esposito L et al (2024) Recurrent glioblastoma \u2014 molecular underpinnings and evolving treatment paradigms. Int J Mol Sci 25(12):6733. https:\/\/doi.org\/10.3390\/ijms25126733","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging therapies for glioblastoma: current state and future directions","volume":"41","author":"Rong L","year":"2022","unstructured":"Rong L, Ni L, Zhang Z (2022) Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res 41:142. https:\/\/doi.org\/10.1186\/s13046-022-02349-7","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"ref5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"23","key":"ref6","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp R","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"issue":"9","key":"ref7","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","article-title":"EANO Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma","volume":"15","author":"Weller M","year":"2014","unstructured":"Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W (2014) EANO Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395\u2013e403. https:\/\/doi.org\/10.1016\/S1470-2045(14)70011-7","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets of diffuse gliomas","volume":"164","author":"Ceccarelli M","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets of diffuse gliomas. Cell 164(3):550\u2013563. https:\/\/doi.org\/10.1016\/j.cell.2015.12.028","journal-title":"Cell"},{"issue":"2","key":"ref9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan CW","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462\u2013477. https:\/\/doi.org\/10.1016\/j.cell.2013.09.034","journal-title":"Cell"},{"issue":"5897","key":"ref10","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons DW","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807\u20131812. https:\/\/doi.org\/10.1126\/science.1164382","journal-title":"Science"},{"issue":"15","key":"ref11","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1158\/1078-0432.CCR-22-3845","article-title":"The clinical and molecular effect of barrier-penetrant therapies in glioblastoma: impact on blood-brain barrier and survival outcomes","volume":"29","author":"Sarkaria JN","year":"2023","unstructured":"Sarkaria JN, Yang L, Grogan P et al (2023) The clinical and molecular effect of barrier-penetrant therapies in glioblastoma: impact on blood-brain barrier and survival outcomes. Clin Cancer Res 29(15):2901\u20132912. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3845","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ref12","doi-asserted-by":"publisher","first-page":"eabc2511","DOI":"10.1126\/sciadv.abc2511","article-title":"Regulation of tumor immune suppression and cancer cell survival by CXCL1\/2 elevation in glioblastoma multiforme","volume":"7","author":"Hu J","year":"2021","unstructured":"Hu J, Zhao Q, Kong L-Y, Wang J, Yan J, Xia X, Jia Z, Heimberger AB, Li S (2021) Regulation of tumor immune suppression and cancer cell survival by CXCL1\/2 elevation in glioblastoma multiforme. Sci Adv 7(5):eabc2511. https:\/\/doi.org\/10.1126\/sciadv.abc2511","journal-title":"Sci Adv"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-020-1137-5","article-title":"DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma","volume":"19","author":"Lu C","year":"2020","unstructured":"Lu C, Wei Y, Wang X, Zhang Z, Yin J, Li W, Chen L, Lyu X, Shi Z, Yan W, You Y (2020) DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer 19(1):28. https:\/\/doi.org\/10.1186\/s12943-020-1137-5","journal-title":"Mol Cancer"},{"issue":"6","key":"ref14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/neuonc\/noad057","article-title":"Trotabresib penetrates the blood-brain-tumor barrier in patients with recurrent high-grade glioma: results from a phase I window-of-opportunity study (CC-90010-GBM-001)","volume":"25","author":"Moreno V","year":"2023","unstructured":"Moreno V, Sep\u00falveda JM, Vieito M et al (2023) Trotabresib penetrates the blood-brain-tumor barrier in patients with recurrent high-grade glioma: results from a phase I window-of-opportunity study (CC-90010-GBM-001). Neuro Oncol 25(6):1113\u20131124. https:\/\/doi.org\/10.1093\/neuonc\/noad057","journal-title":"Neuro Oncol"},{"issue":"7","key":"ref15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a clinical review","volume":"329","author":"Schaff LR","year":"2023","unstructured":"Schaff LR, Mellinghoff IK (2023) Glioblastoma and other primary brain malignancies in adults: a clinical review. JAMA 329(7):574\u2013587. https:\/\/doi.org\/10.1001\/jama.2023.0023","journal-title":"JAMA"},{"issue":"7785","key":"ref16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel FP","year":"2019","unstructured":"Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E et al (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576(7785):112\u2013120. https:\/\/doi.org\/10.1038\/s41586-019-1775-1","journal-title":"Nature"},{"issue":"6167","key":"ref17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson BE","year":"2013","unstructured":"Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY et al (2013) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343(6167):189\u2013193. https:\/\/doi.org\/10.1126\/science.1239947","journal-title":"Science"},{"issue":"9","key":"ref18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/neuonc\/noad095","article-title":"Hemizygous CDKN2A deletion confers worse survival outcomes in IDH-mutant non-codeleted gliomas","volume":"25","author":"Kocakavuk E","year":"2023","unstructured":"Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, Noushmehr H, Verhaak RGW et al (2023) Hemizygous CDKN2A deletion confers worse survival outcomes in IDH-mutant non-codeleted gliomas. Neuro Oncol 25(9):1721\u20131723. https:\/\/doi.org\/10.1093\/neuonc\/noad095","journal-title":"Neuro Oncol"},{"issue":"7239","key":"ref19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton MR","year":"2009","unstructured":"Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458(7239):719\u2013724. https:\/\/doi.org\/10.1038\/nature07943","journal-title":"Nature"},{"issue":"12","key":"ref20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/ng.3441","article-title":"Clock-like mutational processes in human somatic cells","volume":"47","author":"Alexandrov LB","year":"2015","unstructured":"Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S et al (2015) Clock-like mutational processes in human somatic cells. Nat Genet 47(12):1402\u20131407. https:\/\/doi.org\/10.1038\/ng.3441","journal-title":"Nat Genet"},{"issue":"7793","key":"ref21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"Signatures of mutational processes in human cancer","volume":"578","author":"Alexandrov LB","year":"2020","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC et al (2020) Signatures of mutational processes in human cancer. Nature 578(7793):94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3","journal-title":"Nature"},{"issue":"5","key":"ref22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","article-title":"Mutational processes molding the genomes of 21 breast cancers","volume":"149","author":"Nik-Zainal S","year":"2012","unstructured":"Nik-Zainal S, Alexandrov LB, Wedge DC et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979\u2013993. https:\/\/doi.org\/10.1016\/j.cell.2012.04.024","journal-title":"Cell"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/carcin\/bgw055","article-title":"Understanding mutagenesis through delineation of mutational signatures in human cancer","volume":"37","author":"Petljak M","year":"2016","unstructured":"Petljak M, Alexandrov LB (2016) Understanding mutagenesis through delineation of mutational signatures in human cancer. Carcinogenesis 37(6):531\u2013540. https:\/\/doi.org\/10.1093\/carcin\/bgw055","journal-title":"Carcinogenesis"},{"issue":"10","key":"ref24","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak P","year":"2017","unstructured":"Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G et al (2017) A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet 49(10):1476\u20131486. https:\/\/doi.org\/10.1038\/ng.3934","journal-title":"Nat Genet"},{"issue":"12","key":"ref25","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","article-title":"Glioma progression is shaped by genetic evolution and microenvironment interactions","volume":"185","author":"Varn FS","year":"2022","unstructured":"Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P et al (2022) Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 185(12):2184\u20132199e16. https:\/\/doi.org\/10.1016\/j.cell.2022.04.038","journal-title":"Cell"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41698-025-01210-2","article-title":"CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors","volume":"10","author":"Jesus Teles T","year":"2025","unstructured":"Jesus Teles T, Ferrando L, Rodrigues L, Sousa Martins R, Cardoso L, Lopes JM et al (2025) CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors. NPJ Precis Oncol 10:7. https:\/\/doi.org\/10.1038\/s41698-025-01210-2","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"ref27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter SL","year":"2012","unstructured":"Carter SL, Cibulskis K, Helman E et al (2012) Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30(5):413\u2013421. https:\/\/doi.org\/10.1038\/nbt.2203","journal-title":"Nat Biotechnol"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","article-title":"DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal R","year":"2016","unstructured":"Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C (2016) DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol 17(1):31. https:\/\/doi.org\/10.1186\/s13059-016-0893-4","journal-title":"Genome Biol"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ygyno.2018.10.032","article-title":"Analysis of mutational signatures in primary and metastatic endometrial carcinomas reveals distinct patterns of DNA repair defects and progression-associated shifts","volume":"152","author":"Ashley CW","year":"2019","unstructured":"Ashley CW, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N et al (2019) Analysis of mutational signatures in primary and metastatic endometrial carcinomas reveals distinct patterns of DNA repair defects and progression-associated shifts. Gynecol Oncol 152(1):11\u201319. https:\/\/doi.org\/10.1016\/j.ygyno.2018.10.032","journal-title":"Gynecol Oncol"},{"issue":"11","key":"ref30","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1093\/bioinformatics\/bty920","article-title":"gwasurvivr: an R package for genome-wide survival analysis","volume":"35","author":"Rizvi AA","year":"2019","unstructured":"Rizvi AA, Karaesmen E, Morgan M, Preus L, Wang J, Sovic M et al (2019) gwasurvivr: an R package for genome-wide survival analysis. Bioinformatics 35(11):1968\u20131970. https:\/\/doi.org\/10.1093\/bioinformatics\/bty920","journal-title":"Bioinformatics"},{"issue":"7804","key":"ref31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat M","year":"2020","unstructured":"Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL et al (2020) Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580(7804):517\u2013523. https:\/\/doi.org\/10.1038\/s41586-020-2209-9","journal-title":"Nature"},{"issue":"10","key":"ref32","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/neuonc\/noab073","article-title":"Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas","volume":"23","author":"Yu Y","year":"2021","unstructured":"Yu Y, Gaudioso C, Hung W et al (2021) Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol 23(10):1641\u20131654. https:\/\/doi.org\/10.1093\/neuonc\/noab073","journal-title":"Neuro Oncol"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"vdac076","DOI":"10.1093\/noajnl\/vdac076","article-title":"Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma","volume":"4","author":"Daniel P","year":"2022","unstructured":"Daniel P, Meehan B, Sabri S, Jamali F, Sarkaria JN, Choi D et al (2022) Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. Neuro Oncol Adv 4(1):vdac076. https:\/\/doi.org\/10.1093\/noajnl\/vdac076","journal-title":"Neuro Oncol Adv"},{"issue":"10","key":"ref34","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/cncr.33378","article-title":"Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial","volume":"127","author":"Reardon DA","year":"2021","unstructured":"Reardon DA, Kim TM, Frenel JS, Simonelli M, Lopez J, Subramaniam DS et al (2021) Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127(10):1620\u20131629. https:\/\/doi.org\/10.1002\/cncr.33378","journal-title":"Cancer"},{"issue":"2","key":"ref35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4161\/nucl.19090","article-title":"The nuclear envelope protein Nesprin-2 has roles in cell proliferation and differentiation during wound healing","volume":"3","author":"Rashmi RN","year":"2012","unstructured":"Rashmi RN, Eckes B, Gl\u00f6ckner G, Groth M, Neumann S, Gloy J et al (2012) The nuclear envelope protein Nesprin-2 has roles in cell proliferation and differentiation during wound healing. Nucleus 3(2):172\u2013186. https:\/\/doi.org\/10.4161\/nucl.19090","journal-title":"Nucleus"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/onc.2016.172","article-title":"Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response","volume":"36","author":"Nickerson ML","year":"2017","unstructured":"Nickerson ML, Witte N, Im KM, Turan S, Owens CR, Misner K et al (2017) Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene 36(1):35\u201346. https:\/\/doi.org\/10.1038\/onc.2016.172","journal-title":"Oncogene"},{"issue":"4","key":"ref37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s12551-018-0431-6","article-title":"Linker of nucleoskeleton and cytoskeleton (LINC) complex proteins in cardiomyopathy","volume":"10","author":"Stroud MJ","year":"2018","unstructured":"Stroud MJ, Feng W, Zhang X et al (2018) Linker of nucleoskeleton and cytoskeleton (LINC) complex proteins in cardiomyopathy. Biophys Rev 10(4):1033\u20131051. https:\/\/doi.org\/10.1007\/s12551-018-0431-6","journal-title":"Biophys Rev"},{"issue":"6","key":"ref38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ncb1593","article-title":"Positional stability of single DNA double-strand breaks in mammalian cells","volume":"9","author":"Soutoglou E","year":"2007","unstructured":"Soutoglou E, Dorn JF, Sengupta K et al (2007) Positional stability of single DNA double-strand breaks in mammalian cells. Nat Cell Biol 9(6):675\u2013682. https:\/\/doi.org\/10.1038\/ncb1593","journal-title":"Nat Cell Biol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"107097","DOI":"10.1016\/j.yebeh.2020.107097","article-title":"CN, Developmental and epileptic encephalopathy due to SZT2 genomic variants: Emerging features of a syndromic condition","volume":"108","author":"Trivisano M","year":"2020","unstructured":"Trivisano M, Rivera M, Terracciano A, Ciolfi A, Naplitano A, Pepi C et al (2020) CN, Developmental and epileptic encephalopathy due to SZT2 genomic variants: Emerging features of a syndromic condition. Epilepsy Behav 108:107097. https:\/\/doi:10.1016\/j.yebeh.2020.107097","journal-title":"Epilepsy Behav"},{"issue":"2","key":"ref40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cge.13061","article-title":"Novel biallelic SZT2 mutations in 3 cases of early-onset epileptic encephalopathy","volume":"93","author":"Tsuchida N","year":"2018","unstructured":"Tsuchida N, Nakashima M, Miyauchi A, Yoshitomi S, Kimizu T, Ganesan V et al (2018) Novel biallelic SZT2 mutations in 3 cases of early-onset epileptic encephalopathy. Clin Genet 93(2):266\u2013274. https:\/\/doi.org\/10.1111\/cge.13061","journal-title":"Clin Genet"},{"issue":"7645","key":"ref41","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nature21423","article-title":"KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1","volume":"543","author":"Wolfson RL","year":"2017","unstructured":"Wolfson RL, Chantranupong L, Wyant GA, Gu X, Orozco JM, Condon KJ et al (2017) KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. Nature 543(7645):438\u2013442. https:\/\/doi.org\/10.1038\/nature21423","journal-title":"Nature"},{"issue":"6369","key":"ref42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1126\/science.aao2625","article-title":"Sestrin2 is a leucine sensor for the mTORC1 pathway","volume":"358","author":"Wolfson RL","year":"2017","unstructured":"Wolfson RL, Chantranupong L, Saxton RA et al (2017) Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 358(6369):813\u2013818. https:\/\/doi.org\/10.1126\/science.aao2625","journal-title":"Science"},{"issue":"28","key":"ref43","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.1038\/s41388-019-0860-6","article-title":"mTOR signaling in glioblastoma: a key pathway that drives tumor growth and progression","volume":"38","author":"Langhans SA","year":"2019","unstructured":"Langhans SA, Gopal P, Kleinberg LR et al (2019) mTOR signaling in glioblastoma: a key pathway that drives tumor growth and progression. Oncogene 38(28):6348\u20136360. https:\/\/doi.org\/10.1038\/s41388-019-0860-6","journal-title":"Oncogene"},{"issue":"6","key":"ref44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1469-7580.2010.01207.x","article-title":"Expression of fibrillin-3 during human embryonic development and its potential roles in morphogenesis","volume":"217","author":"Sabatier L","year":"2010","unstructured":"Sabatier L, Tajbakhsh S, Marie P-J, Chappard D, Rohmer V, Fouchet P et al (2010) Expression of fibrillin-3 during human embryonic development and its potential roles in morphogenesis. J Anat 217(6):719\u2013729. https:\/\/doi.org\/10.1111\/j.1469-7580.2010.01207.x","journal-title":"J Anat"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"924362","DOI":"10.3389\/fgene.2022.924362","article-title":"Case report: a novel homozygous missense variant of FBN3 supporting it is a new candidate gene causative of a Bardet\u2013Biedl syndrome-like phenotype","volume":"13","author":"Genovesi ML","year":"2022","unstructured":"Genovesi ML, Torres B, Goldoni M, Salvo E, Cesario C, Majolo M et al (2022) Case report: a novel homozygous missense variant of FBN3 supporting it is a new candidate gene causative of a Bardet\u2013Biedl syndrome-like phenotype. Front Genet 13:924362. https:\/\/doi.org\/10.3389\/fgene.2022.924362","journal-title":"Front Genet"},{"issue":"6","key":"ref46","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/oby.2012.14","article-title":"Impact of FBN3 gene variants on metabolic phenotypes in polycystic ovary syndrome","volume":"20","author":"Yalamanchi SK","year":"2012","unstructured":"Yalamanchi SK, Sam S, Cardenas MO (2012) Impact of FBN3 gene variants on metabolic phenotypes in polycystic ovary syndrome. Obesity 20(6):1273\u20131278. https:\/\/doi.org\/10.1038\/oby.2012.14","journal-title":"Obesity"},{"issue":"12","key":"ref47","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/neuonc\/noad123","article-title":"FBN3 mutations and their association with temozolomide resistance in glioblastoma","volume":"25","author":"Zhao J","year":"2023","unstructured":"Zhao J, Li Y, Yang L, Li W, Li X, Zhang X et al (2023) FBN3 mutations and their association with temozolomide resistance in glioblastoma. Neuro Oncol 25(12):1882\u20131893. https:\/\/doi.org\/10.1093\/neuonc\/noad123","journal-title":"Neuro Oncol"},{"key":"ref48","author":"Lecat A","year":"2012","unstructured":"Lecat A, Di Valentin E, Somja J, Jourdan S, Fillet M, Kufer TA et al (2012) The c-Jun N-terminal kinase-binding protein (JNKBP1) acts as a negative regulator of NOD2 protein signaling by inhibiting its oligomerization process. J Biol Chem. ;287(35) (This reference appears truncated in your source list \u2014 please complete volume\/pages\/DOI before submission.)"},{"issue":"6","key":"ref49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.stem.2018.04.009","article-title":"JUN N-terminal kinase signaling regulates lineage-specific neural differentiation of embryonic stem cells","volume":"22","author":"Xue Y","year":"2018","unstructured":"Xue Y, Shen Y, Liu Y et al (2018) JUN N-terminal kinase signaling regulates lineage-specific neural differentiation of embryonic stem cells. Cell Stem Cell 22(6):861\u2013875e7. https:\/\/doi.org\/10.1016\/j.stem.2018.04.009","journal-title":"Cell Stem Cell"},{"issue":"2","key":"ref50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ajhg.2016.12.011","article-title":"Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent nephronophthisis","volume":"100","author":"Macia MS","year":"2017","unstructured":"Macia MS, Halbritter J, Delous M, Bredrup C, Gutter A, Filhol E et al (2017) Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent nephronophthisis. Am J Hum Genet 100(2):323\u2013333. https:\/\/doi.org\/10.1016\/j.ajhg.2016.12.011","journal-title":"Am J Hum Genet"},{"issue":"5","key":"ref51","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.kint.2023.01.032","article-title":"Novel TRIM8 and MAPKBP1 variants in nephronophthisis and Wilms tumor","volume":"103","author":"Salomon R","year":"2023","unstructured":"Salomon R, Braun DA, Gee HY et al (2023) Novel TRIM8 and MAPKBP1 variants in nephronophthisis and Wilms tumor. Kidney Int 103(5):1120\u20131131. https:\/\/doi.org\/10.1016\/j.kint.2023.01.032","journal-title":"Kidney Int"},{"issue":"2","key":"ref52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/1389450116666150126111055","article-title":"The role of JNK signalling in responses to oxidative DNA damage","volume":"17","author":"Shaukat Z","year":"2016","unstructured":"Shaukat Z, Liu D, Hussain R, Khan M, Gregory SL (2016) The role of JNK signalling in responses to oxidative DNA damage. Curr Drug Targets 17(2):154\u2013163. https:\/\/doi.org\/10.2174\/1389450116666150126111055","journal-title":"Curr Drug Targets"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9093330\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9093330\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:14:28Z","timestamp":1773414868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9093330\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":52,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9093330\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,3,13]]},"subtype":"preprint"}}